Journal of AIDS & Clinical Research

Marli Jane Martins Costa

Publications

• Research Article
  Pharmacological Interaction of Lopinavir/Ritonavir 800/200 mg BID and Rifampicin in Subjects Presenting Tuberculosis with Contraindication for an Efavirenz containing Antiretroviral Regimen
  Author(s): Carolina Arana Stanis Schmaltz, Marli Jane Martins Costa, Vitoria Berg Cattani, Douglas Pereira Pinto, Jose Liporage, Aline Benjamin, Catherine Boulanger, Mariza Morgado and Valeria RollaCarolina Arana Stanis Schmaltz, Marli Jane Martins Costa, Vitoria Berg Cattani, Douglas Pereira Pinto, Jose Liporage, Aline Benjamin, Catherine Boulanger, Mariza Morgado and Valeria Rolla
  
  Rifampicin reduces plasma concentration of most HIV protease inhibitors. Lopinavir boosted with ritonavir (LPV/r) could be an option to treat TB-HIV patients. Our aim was to evaluate lopinavir interaction with rifampicin during TB-HIV therapy. TB-HIV patients who could not use efavirenz and with no genotypic resistance to lopinavir were included. Rifampicin 600 mg, isoniazid 400 mg and pyrazinamide 2000 mg were started at day one for 6 months and LPV/r plus two nucleoside/nucleotide reverse transcriptase inhibitors were introduced at day 30. LPV/r dose was started at 400/100 mg BID and escalated over 7 days to 800/200 mg BID. Pharmacokinetic sampling was performed at day 15 (rifampicin), 45, 90, 180 (rifampicin, lopinavir, ritonavir) and 210 (lopinavir, ritonavir). Viral load (VL) and CD4 counts were performed at baseline and days 30, 60, 120, and 180. Genotypic testing was done in ba.. Read More»
  DOI: 10.4172/2155-6113.1000358

  Abstract PDF